Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.

Sidharth V. Puram, Douglas R. Adkins, Jared Cohen et al.|Journal of Clinical Oncology|2023

Cited by 4